ARX788, a novel anti-HER2 antibody-drug conjugate, shows anti-tumor effects in preclinical models of trastuzumab emtansine-resistant HER2-positive breast cancer and gastric cancer
Márk Barok, Vadim Le Joncour, Ana Martins, Jorma Isola, Marko Salmikangas, Pirjo Laakkonen, Heikki Joensuu
Topics & Concepts
Trastuzumab emtansineTrastuzumabAntibody-drug conjugateConjugateMedicineCancerAntibodyBreast cancerDrugOncologyCancer researchPharmacologyInternal medicineMonoclonal antibodyImmunologyMathematicsMathematical analysisHER2/EGFR in Cancer ResearchMonoclonal and Polyclonal Antibodies ResearchCell Adhesion Molecules Research